Clinical Trial Update: A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

View source ↗

Summary

A real-world study in HR+/HER2- advanced/metastatic breast cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer

Snippet

Sponsor: SciClone Pharmaceuticals | Conditions: Breast Cancer Metastatic, HR+/HER2- Advanced Breast Cancer | Status: WITHDRAWN